miR-3113-5p, miR-223-3p, miR-133a-3p, and miR-499a-5p are Sensitive Biomarkers to Diagnose Sudden Cardiac Death

Fengping Yan (✉ tomjiangxi@163.com)
Gannan Medical College

Yuanyuan Chen
Department of Forensic Medicine, Gannan Medical University

Xing Ye
Department of Forensic Medicine, Gannan Medical University

Fu Zhang
Criminal Technology Center of Guangdong Province Public Security Bureau

Shiquan Wang
Department of Forensic Medicine, Gannan Medical University

Le Zhang
Department of Forensic Medicine, Gannan Medical University

Xiaoting Luo
Department of Biochemistry and Molecular Biology, Gannan Medical University

Research

Keywords: miRNA, sudden cardiac death, molecular pathology, biomarkers

DOI: https://doi.org/10.21203/rs.3.rs-147657/v1

License: © izzasl This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Sudden cardiac death (SCD) remains a great health threat and diagnostic challenge, especially those cases without positive autopsy findings. Molecular biomarkers have been urgently needed for the diagnosis of SCD displaying negative autopsy results. Due to their nature of stability, microRNAs (miRNAs) have emerged as promising diagnostic biomarkers for cardiovascular diseases.

Methods

This study investigated whether specific cardio-miRNAs (miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p) could serve as potential biomarkers for the diagnosis of SCD. Thirty-four SCD cases were selected, 18 categorized as acute myocardial infarction (AMI) without positive autopsy findings and 16 as atherosclerotic cardiovascular diseases (ASCVD) with gross myocardial scar. Carbon monoxide (CO) intoxication (n=14) and fatal injury death (n=14) that displayed no pathological changes of myocardium were selected as control group, respectively. Histological analyses were performed to reveal the pathological changes and real-time quantitative polymerase chain reaction (RT-qPCR) was used to determine the expression of those miRNAs.

Results

It showed that heart samples from the AMI group displayed no remarkable difference with regard to the expression of cleaved-caspase3, CD31, and CD68 and the extent of fibrotic tissue accumulation when compared with control samples. The four cardio-miRNAs were significantly up-regulated in the SCD samples as compared with control. When discriminating SCD from controls, ROC curve analysis revealed that the areas under the curve (AUC) of these 4 miRNAs were from 0.7839 to 0.9043 with sensitivity of 64.71-97.06% and specificity of 70-100%. Moreover, when discriminating the specific causes of SCD, the four miRNA expressions increased in the AMI heart as relative to ASCVD, and a combination of two miRNAs presented higher diagnostic value (AUC=0.7407-0.8667).

Conclusion

miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p may serve as independent diagnostic biomarkers for SCD, and a combination of two of these miRNAs could further discriminate detailed causes of SCD.

Background

Heart serves as a biological pump that circulates blood throughout our bodies and thus supplying us with oxygen and nutrients. Irregular cardiac activities can restrict blood supply and lead to sudden cardiac death (SCD)[1]. SCD is one of the major causes of natural death, which is defined as an unexpected fatal event occurring within 1 h from the onset of symptoms in an apparently healthy subject[2,3]. SCD causes approximately 1 million of adult deaths in China each year and remains one of the most challenging tasks in cardiology[4]. Coronary artery diseases closely associate with the high incidence of SCD cases, particularly myocardial infarction (MI)[5]. Acute MI (AMI) is a specific cause of SCD that often claims deaths in a short period. Unfortunately, deaths from AMI often show negative autopsy findings, and it is not easy to accurately diagnose with the current histopathology techniques. Moreover, data suggested that though implantable cardioverter defibrillators (ICD) have being used to prevent SCD in individuals with existing conditions of cardiomyopathy and inherited arrhythmias[6], their survival
benefits are limited as only 20–30% even under appropriate therapy[7]. In addition, albeit left ventricular systolic
dysfunction and the severity of heart failure symptoms being predictors of SCD[8] , a considerable number of SCD
events do not have a pre-existing history of depressed ejection fraction or a clinical history of heart failure[9,10].
Furthermore, some SCD cases cannot be explained even after systemic autopsy and histological examination.
These cases have been postulated to die largely from AMI without grossly observable pathology[11]. Therefore, it
is an imperative to find sensitive biomarkers that could be used for detection of SCD, especially AMI.

Currently, mutations of cardiac-related genes have been implicated in the pathogenesis of SCD, such as
MYBPC3[12] , ACE[13] and PKP2[14] . For example, the ACE DD genotype was associated with a 3.35-fold higher
risk of AMI, and a significantly higher risk of SCD (odds ratio (OR) = 6.484, 95% confidence interval (CI): 1.036-
40.598, p = 0.046)[13] . Inflammation is also reported to play a pivotal role in the pathogenesis of atherosclerosis
and cardiovascular disease, with c-reactive protein (CRP) emerging as inflammatory biomarker in AMI[15,16].

In addition to the above macromolecules, noncoding RNAs have recently received great attention for their potential
as diagnostic biomarkers[17]. MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression at a
post-transcriptional level by repressing messenger RNA (mRNA) translation mainly via binding at the
complementary 3'-untranslated region[18,19]. It has been widely recognized that miRNAs can serve as vital players
in many biological processes, especially in the cardiovascular diseases[20,21]. Studies have shown that aberrant
miRNAs expression closely related to AMI[22] , hypertension[23], atherosclerosis[24], and arrhythmias[25]. miR-
223 enhanced cardiac fibroblasts proliferation, migration, and differentiation, which led to cardiac fibrosis partially
via the involvement of RASA1[26] . miR-133a plays an important role in atherosclerosis by attenuating lipid
accumulation via TR4-CD36 pathway in macrophages[27]. miRNA-499 levels were found to be linearly proportional
to myocardial damage, with close relationship with AMI[28] . All these miRNAs have been identified as originating
from the heart or being heart-resided, making them possible candidates for the diagnostic biomarkers of
cardiovascular diseases. However, despite a large number of studies in identifying biomarkers to improve SCD
diagnostic efficiency, few biomarkers have progressed to clinical use for SCD.

Given miRNAs’ stability and potential role in various cardiovascular events such as SCD, the aim of the present
study is to investigate the value of four cardio-miRNAs (miR-3113-5p, miR-223-3p, miR-133a-3p, and miR-499a-5p)
in discriminating SCD from controls. Our data showed that each of these miRNAs had considerable sensitivity
when discriminating the SCD from non-cardiac deaths, and a combination of two of these miRNAs could further
efficiently discriminate detailed causes of SCD.

**Methods**

**Human heart samples**

For the purpose of this study, we collected four categories of human heart samples that were autopsied at the
Department of Forensic Medicine, School of Basic Medical Sciences, Gannan Medical University over the period
2012-2019. A total of 34 cases of subjects who died for SCD were selected. These cases included 18 of AMI that
presented none notable heart changes at autopsy and 16 of ASCVD with evidence of heart dysfunction. The
causes of SCD were made after systemic autopsy. AMI was defined as sudden deaths without heart gross
pathology, with or without mild coronary artery stenosis. ASCVD was defined as sudden deaths in clinic plus
severe coronary artery stenosis at autopsy, often with gross or microscopic scarring surrounding myocardium. In
addition, 14 cases of fatal injury and 14 cases of carbon monoxide (CO) intoxication were selected as the year-
matched control cases. Patients who had pre-operative chemo- or radiotherapy history were excluded. Any case with heart implantation was also excluded. All of these cases undergone autopsy examination and were also excluded from influence of other potential substances such as alcohol, illicit drugs, or psychoactive drugs. Detailed information regarding the four categories of cases were documented in Table 1. The use of human heart samples for the purpose of research was approved by the Ethical Review Board at the School of Basic Medical Sciences, Gannan Medical University.

**Histological evaluation**

All histological evaluation was performed using the human heart samples dissected from the apex of each heart. Due to difficulty in obtaining fresh surgical heart samples, we used the autopic FFPE samples for the purpose of this study. Unlike mRNAs or proteins that are prone to degradation and chemical modification, miRNAs are very small in size (~22nt), less likely to be degraded, and easier to recover from FFPE samples, all of which confer to miRNAs high forensic relevance[29]. The extraction of miRNAs from autopic FFPE samples was commonly documented in publications[30]. After histological staining, independent pathologists were recruited to review the Hematoxylin & Eosin (H&E) staining sections and PicroSirius Red (PSR) staining sections using a multi-head microscope to result in consensus.

For the H&E staining, human heart tissues were immediately fixed in 10% neutral formaldehyde for 24 hours, followed by embedding in paraffin. Tissues were then sliced into 5 µm-thick heart slices. Then the slices were dewaxed and dehydrated in a gradient alcohol. Endogenous peroxidase activity was blocked using 3% H₂O₂ solution. The antigen retrieval was performed by steam heating in 10 mM citrate buffer (pH 6.0) for 10 minutes. Slices were then stained with hematoxylin solution for 10 min at room temperature and incubated in 1% hydrochloric-alcohol solution. Then, slices were washed using tap water, stained with eosin solution for 5 minutes, and separated by 75%, 85%, 90%, 95%, 100%, and 100% alcohol solutions for 2 minutes, respectively. Next, the slices were dried and sealed with neutral gums. After H&E staining, the morphological changes were observed and photographed under an optical microscope (Olympus, Tokyo, Japan).

For the PSR staining, human heart slices were deparaffinized to water and then immersed in 0.1% Sirius red staining solution dissolved in picric acid for 1 hour. Then slices were washed in acidified water containing 1.5% hydrogen chloride, dehydrated and mounted. Collagen and non-collagen components were red- and orange-stained, respectively.

**Immunohistochemistry (IHC) staining**

Heart slices from the four categories were also subject to IHC analysis. Briefly, the slides were incubated in 3% H₂O₂ solution for 10 minutes and antigen retrieval was performed by steam heating in 10 mM citrate buffer (pH 6.0) for 30 minutes. After epitope recovery, the slides were then treated with 10% of normal goat serum for 60 minutes, followed by incubation with active caspase 3 antibody (1:500, Cell Signaling Technology, Catlog #9664, MA, USA), CD31 antibody (1:1000, Cell Signaling Technology, Catlog #3528), and CD68 antibody (1:500, Cell Signaling Technology, Catlog #76437) incubation overnight at 4°C. The slides were washed and incubated with secondary horseradish peroxide (HRP)-linked secondary antibody (Vector Laboratories, MN, USA) at 1:500 dilutions for 1 hour. The samples were treated with the chromogen DAB for antigen detection and the final counterstaining was performed with hematoxylin.

**RNA extraction and reverse Transcription**
All paraffin was removed from the FFPE heart sections by treating with Deparanization Solution. The extraction of miRNAs from FFPE tissues was performed using a commercial miRNeasy FFPE kit (Qiagen, Catalog #217504, Hilden, Germany). Briefly, samples were incubated by heat treatment in an optimized lysis buffer, which contains proteinase K, to release RNAs from the sections. Supernatant was collected and treated with a DNase, followed by buffer RBC and ethanol treatments. The cleaned samples were then applied to an RNeasy MiniElute spin column, where the total RNAs including miRNAs, bound to the membrane and contaminants were efficiently washed away. Total RNAs including miRNAs were then eluted in a minimum of 14 μL of RNase-free water. Reverse transcription of the total RNA was performed using a Mir-X miRNA First-Strand Synthesis Kit (Takara, Tokyo, Japan) for RT-qPCR of miRNA. The synthesized cDNA was stored at -80 °C for later use.

Real-time quantitative polymerase chain reaction (RT-qPCR)

QuantiFast Multiplex RT-PCR Kit (Qiagen) was used for RT-qPCR analysis. According to the kit instructions, an aliquot of 25 μL reaction system was mixed and amplified using the Applied Biosystem 7500 fluorescence quantitative PCR instrument (Darmstadt, Germany). Primers used for this study were listed in Table 2. The 2^ΔCt method was used to calculate the relative expression of the target genes where ΔCt_{miRNA}=Ct_{miRNA}-Ct_{housekeeping}.

Statistical analysis

All data were expressed as mean ± standard error of the mean (SEM). Statistical analysis was performed using independent Student's t test. The diagnostic powers of miR-3113-5p, miR-223-3p, miR-133a-3p, and miR-499a-5p were evaluated by receiver operating characteristic (ROC) analysis. Areas under the curve (AUCs) were calculated. All statistical analyses were performed using GraphPad Prism 8.0 software (La Giolla, CA, USA). P < 0.05 was considered as statistically significant.

Results

SCD cases categorized as AMI did not show notable pathological changes

We conducted both H&E staining and PSR staining to compare the histological changes among groups. As expected, heart samples from the ASCVD group displayed severe coronary stenosis, occasionally accompanied with calcification, and myocardium was disarrayed with a halo of fibrotic tissues surrounding the degenerated myocardium. In great contrast, heart samples from the AMI group showed regular myocardium arrangement without notable accumulation of fibrotic tissues, albeit local rupture of myocardial fiber in some areas (Fig. 1).

Common molecular markers failed to discriminate the SCD cases categorized as AMI from control cases

To further examine molecular alterations in the heart samples of SCD, we assayed the common molecular biomarkers of myocardial injury, including cl-Casp3 (a marker of cell apoptosis), CD31 (a marker for vascular endothelium), and CD68 (a marker of macrophage). As expected, the heart samples from the ASCVD group showed remarkable expression of cl-Casp3 and CD68. Neovascularization was also evident in the ASCVD group as by IHC staining of CD31. Unlike the ASCVD, the AMI group showed dim expression of the above markers. In fact, the heart samples from the AMI group were analog to those from the control ones with regard to these assessed markers (Fig. 2). These data suggested that AMI was hard to be discriminated using the histological and IHC assays.
miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p significantly upregulated in the SCD

In view that common histological and IHC techniques could not aid in diagnosing AMI, we speculated that small-molecules might be helpful. We thus assessed whether four cardio-miRNAs (miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p) had any diagnostic values. The selection of these miRNAs was based on published literature[30-32] and our previous work[33]. Our aims were two-fold: one to assess whether these miRNAs could diagnose SCD, and the other one to assess whether specific miRNAs had higher efficacy as to discriminate the causes of SCD. To this end, we initially pooled the ASCVD and AMI groups as SCD cases. RT-qPCR was performed with U6 as a stable reference gene. Our results revealed that miR-3113-5p was significantly elevated by approximate five-fold in the SCD groups (Fig. 3A). miR-223-3p and miR-499a-5p were also increased by approximate five-fold (Fig. 3B and 3C). miR-133a-3p showed significant increases for approximate three-fold when compared to both controls (Fig. 3D).

miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p could aid in diagnosing SCD

We next assessed the diagnostic values of these miRNAs for distinguishing SCD from non-cardiac deaths. Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of miR-3113-5p were 0.7893 (SCD vs Fatal injury: 95% confidence interval (CI) = 0.6501 to 0.9176, sensitivity = 68.75% and specificity = 83.33%) and 0.8281 (SCD vs CO intoxication: 95% CI = 0.7071 to 0.9492, sensitivity = 68.75% and specificity = 91.67%) (Fig. 4A and 4B). The AUCs of miR-223-3p were 0.9043 (SCD vs Fatal injury: 95% CI = 0.8031 to 1.006, sensitivity = 83.33% and specificity = 88.89%) and 0.8917 (SCD vs CO intoxication: 95% CI = 0.7984 to 0.9849, sensitivity =75% and specificity = 100%) (Fig. 4C and 4D). The AUCs of miR-499a-5p were 0.8971 (SCD vs Fatal injury: 95% CI = 0.7972 to 0.9969, sensitivity = 82.35% and specificity = 90%) and 0.8853 (SCD vs CO intoxication: 95% CI = 0.7771 to 0.9935, sensitivity =97.06% and specificity = 70%) (Fig. 4E and 4F). The AUCs of miR-133a-3p were 0.7851 (SCD vs Fatal injury: 95% CI = 0.6466 to 0.9235, sensitivity = 67.65% and specificity =76.92%) and 0.8743 (SCD vs CO intoxication: 95% CI = 0.7933 to 0.9793, sensitivity =64.71% and specificity = 100%), respectively (Fig. 4G and 4H). Detailed ROC analysis results were listed in Table 3. These results demonstrated that miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p could be used as sensitive biomarkers for diagnosis of SCD.

miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p were significantly up-regulated in the AMI group compared with the ASCVD group

To precisely evaluate the power of the four miRNAs in predicting SCD, SCD was divided into ASCVD (with gross coronary artery stenosis) and AMI (without notable heart changes). Meanwhile, the expression patterns of four miRNAs were detected in ASCVD and AMI group by RT-qPCR. Interestingly, miR-3113-5p (Fig. 5A), miR-223-3p (Fig. 5B), miR-499a-5p (Fig. 5C), and miR-133a-3p (Fig. 5D) were all significantly higher in the AMI group than those in the ASCVD group with the fold-change ranging from two to three (p<0.05).

Diagnostic efficiency of the miRNAs in discriminating the detailed causes of SCD

Next, ROC curve analyses were used to assess the diagnostic ability of the four miRNAs for discriminating AMI from ASCVD. It revealed that neither of these miRNAs alone could efficiently discriminate AMI (AUC was 0.7373 for miR-3113-5p, AUC was 0.7200 for miR-223-3p, AUC was 0.7569 for miR-133a-3p and AUC was 0.7951 for miR-499a-5p), indicating that AMI and ASCVD both shared common pathologic basis, albeit AMI occurring in a sudden and unidentified way. We then assessed the ROC by combing these miRNAs. Our results showed that the AUC of a
combination of miR-3113-5p and miR-223-3p was 0.8667 (95% CI = 0.7388 to 0.9945, sensitivity = 82.35% and specificity = 80%, Fig. 6A). The AUC of a combination of miR-3113-5p and miR-499a-5p was 0.8510 (95% CI = 0.7105 to 0.9915, sensitivity = 100% and specificity = 66.67%, Fig. 6B). The AUC of a combination of miR-3113-5p and miR-133a-3p was 0.7686 (95% CI = 0.6032 to 0.9341, sensitivity = 70.59% and specificity = 80%, Fig. 6C). The AUC of a combination of miR-499a-5p and miR-133a-3p was 0.7569 (95% CI = 0.5938 to 0.9201, sensitivity = 66.67% and specificity = 81.25%, Fig. 6D). The AUC of a combination of miR-223-3p and miR-499a-5p was 0.7741 (95% CI = 0.6062 to 0.9419, sensitivity = 88.89% and specificity = 60%, Fig. 6E). The AUC of a combination of miR-223-3p and miR-133a-3p was 0.7407 (95% CI = 0.5700 to 0.9115, sensitivity = 66.67% and specificity = 80%, Fig. 6F). The details were shown in Table 4. These results demonstrated that miR-3113-5p and miR-223-3p together yielded the highest diagnostic performance in discriminating AMI from ASCVD (maximum of AUC). miR-3113-5p and miR-499a-5p together also showed high AUC values and sensitivity (maximum of Youden's index).

Discussion

Cardiovascular disease is still the main cause of morbidity and mortality worldwide. miRNAs play important roles in regulating cardiac development, remodeling and regeneration, endothelial function, vasculogenesis and neoangiogenesis through a variety of pathways[34]. Aberrant miRNA expression profiles are associated with various cardiovascular conditions such as hypertrophy, fibrosis, heart failure, and arrhythmias[35,36]. Studies have shown that miRNAs are circulating freely in mammalian blood with marked biostability and can be detected with high sensitivity and specificity in human plasma and serum[37]. So, the diagnostic potential of miRNA detection in human plasma for cardiovascular disorders was to be explored. Coronary artery disease is the main cause of SCD. It was reported that the circulating miR-1[38] and miR-208a[39] significantly increased in AMI patients compared to non-AMI controls, indicating miR-1 and miR-208a in serum may serve as biomarkers for AMI. miR-1 is also upregulated in the heart from patients with coronary artery disease and in rat ischemic hearts, which correlates to an increase in arrhythmogenesis[40]. miR-135a increased and miR-147 decreased significantly in plasma of ASCVD patients, and miR-135a/miR-147 ratio could be used for ASCVD diagnosis[41]. Circulating miR-106a may function as potential biomarker in patients with coronary artery disease[42]. Although there has been many researches focused on circulating/plasma biomarkers to enhance SCD risk prediction and diagnostic performance, few cardio-miRNAs have previously been identified, and none of these biomarkers have progressed to clinical use for SCD. Thus, there remains a critical need to identify biomarkers of SCD.

Several studies have reported that miR-223 is associated with myocardial diseases. miR-223-3p inhibits ischemia-reperfusion induced cardiac necroptosis at multiple layers which may constitute a new therapeutic agent for the treatment of ischemic heart disease[31]. miR-223 was also showed to be downregulated in ET-1 induced hypertrophic myocardium by targeting TNNI3K[43]. miR-223 was upregulated in a rat model of AMI and its overexpression promoted cardiac arrhythmias[26]; thus, miR-223 may be a new target in the treatment of ischemic arrhythmias. Our previous research showed that cardiac miR-3113-5p might be a useful target for therapeutic purposes and circulating miR-3113-5p might serve as a stable marker for early diagnosis of cardiac ischemia-reperfusion injury[33]. miR-499-5p is highly conserved and preferentially expressed in the myocardium[44], circulating levels of miR-499-5p were significantly higher at admission in AMI patients that died within the following year as compared to those that survived the cardiovascular event[45]. Overexpression of miR-499-5p in cardiomyocytes was able to protect the heart against myocardial infarction-associated tissue damage in vivo[46]. A study reported that miR-133a-3p inhibits cardiomyocyte apoptosis by targeting caspase-9[47], and miR-133a-3p
has been implicated in the control of myocardial fibrosis[48]. The above reports suggested these microRNAs had clinical importance in the diagnosis of SCD.

In this study, we have evaluated whether the above four miRNAs were potential biomarkers to differentiate and diagnose SCD in actual human cases. Our study demonstrated that miR-3113-5p, miR-223-3p, miR-499a-5p and miR-133a-3p may serve as candidate diagnostic biomarkers for SCD, allowing to distinguish subjects with SCD from others. The present study showed that the expression levels of miR-3113-5p, miR-223-3p, miR-499a-5p and miR-133a-3p were significantly up-regulated in the heart tissues from SCD as compared to control subjects. The ROC analysis revealed that the four miRNAs may serve as independent diagnostic markers of SCD. Among the miRNAs, miR-223-3p and miR-499a-5p showed better accuracy with the highest AUC values. In particular, we further found that several miRNA panels consisting two of the four miRNAs could achieve better discriminative capacity when discriminating the causes of SCD. These results showed that miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p may be considered as potential candidate biomarkers for diagnosis of SCD.

Previous studies have focused on circulating miRNAs that may be novel biomarkers for AMI or SCD. For example, an elevated level of circulating miR-133a may serve as a diagnostic marker of AMI[49]. Circulating miR-499 and miR-223 can effectively differentiate AMI from non-AMI patients [50,51]. Unfortunately, these studies mainly focused on plasma or serum samples. The role of these miRNAs at their origin (cardiac-derived miRNAs, cardio-miRNAs) remained largely unknown. To this end, we used human heart samples to evaluate these cardio-miRNAs in SCD cases. Archival FFPE heart tissue samples are readily available resources for miRNA biomarker identification[52]. It has been demonstrated that miR-1, miR-499, miR-133 and miR-208 are sensitive markers to diagnose AMI and SCD using post-mortem FFPE heart tissues[30], an observation that was also confirmed by the current study. In addition, our study represents the first one, to the best knowledge of us, to report the expression profiling of miR-3113-5p and miR-223-3p in FFPE heart tissues, and extended their biological importance as a diagnostic biomarker for SCD or AMI.

For a long time, the study of miRNAs could only be performed in model animals which was defected from clinical and forensic reality. The present study used FFPE tissues as a novel research material to maximally promote the findings conforming with human bodies. FFPE samples are valuable research materials, stored in pathology archives worldwide. Storing FFPE specimens is more economical than storing frozen samples, and the histological structure can be preserved almost permanently[52]. However, formalin fixation and paraffin embedding inevitably lead to nucleic acids degradation in these tissues DNA and RNA are fragmented and chemically modified [53], which sometimes causes inconsistency between the results obtained using matched fresh or FFPE samples[54]. Fortunately, miRNAs are robust and stable in FFPE heart tissue, which can be utilized as deep sequencing and quantitative qPCR analyses of miRNAs[55]. It was found that miRNAs remain highly stable in postmortem FFPE heart tissues, and validated that miR-1, miR-208b, and miR-499a in FFPE heart tissues were diagnostic biomarkers for AMI patients[30]. Therefore, we believe that the use of FFPE as a clinic relevant material opens novel insights into disease pathogenesis, particularly with regard to the identification of miRNAs.

Conclusions

Our study showed the potential of miR-3113-5p, miR-223-3p, miR-499a-5p, and miR-133a-3p as candidate biomarkers for diagnosis of SCD. We propose that individual of miR-3113-5p, miR-223-3p, miR-133a-3p, and miR-499a-5p can serve as sensitive biomarkers to diagnose SCD, and a pool of these miRNAs could be further used to discriminate the causes of SCD, particularly the cases without positive autopsy findings.
Abbreviations

SCD, sudden cardiac deaths. AMI, acute myocardial infarction. CO, carbon monoxide. ASCVD, atherosclerotic cardiovascular disease. AUC, area under the curve. CI, confidence interval. miRNA, microRNA. OR, odds ratio. H&E, Hematoxylin & Eosin. PSR, PicroSirius Red. FFPE, formalin-fixed paraffin-embedded. IHC, immunohistochemistry. IHC, horseradish peroxide. LB, lower bound; UB, upper bound

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board at the Gannan Medical University (approval number 2019161). Additional informed consent was not required by the IRB since this study only re-used the FFPE blocks that have already been archived after forensic medical examination.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Consent for publication

Not applicable.

Competing Interests

The authors declare that they have no competing interests.

Funds

This work was financially funded by the open project of Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education (No. XN201810), the Research Project of Gannan Medical University (No. XN201924 and YB201811), the Science and Technology Project of Jiangxi Provincial Department of Education (No.: GJJ160979 and GJJ180794), and the open project of Key Laboratory of Forensic Pathology, Ministry of Public Security (GAFYBL201903).

Authors’ contributions

F. Y., Y. C., and X. Y. collected human specimens and performed the IHC and PCR analysis. F. Z., and S. W. drafted the manuscript. L. Z. helped in data analysis. F. Y., and X. L. revised the manuscript and contributed to the discussion.

References

1. Fukuda K, Kanazawa H, Aizawa Y, Ardell JL, Shivkumar K. Cardiac innervation and sudden cardiac death. Circ Res 2015;116(12):2005-19.
2. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC. The incidence of sudden cardiac death in the general population. J Clin Epidemiol 2004;57(1):98-102.
3. Isbister J, Semsarian C. Sudden cardiac death: an update. Intern Med J 2019;49(7):826-833.
4. Shan H, Li X, Pan Z, Zhang L, Cai B, Zhang Y, Xu C, Chu W, Qiao G, Li B and others. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol 2009;158(5):1227-35.

5. Chatterjee NA, Levy WC. Sudden cardiac death after myocardial infarction. Eur J Heart Fail 2020;22(5):856-858.

6. Borne RT, Katz D, Betz J, Peterson PN, Masoudi FA. Implantable Cardioverter-Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review. J Am Heart Assoc 2017;6(3).

7. Myerburg RJ, Goldberger JJ. Sudden Cardiac Arrest Risk Assessment: Population Science and the Individual Risk Mandate. JAMA Cardiol 2017;2(6):689-694.

8. El-Battrawy I, Borggrefe M, Akin I. The Risk for Sudden Cardiac Death and Effect of Treatment with Sacubitril/Valsartan in Heart Failure. JACC Heart Fail 2019;7(11):999.

9. Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow RO, Buxton AE, Chen PS, Estes M, Jouven X and others. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010;122(22):2335-48.

10. Corrado D, Zorzi A, Vanoli E, Gronli E. Current challenges in sudden cardiac death prevention. Heart Fail Rev 2020;25(1):99-106.

11. Basso C, Carturan E, Pilichou K, Rizzo S, Corrado D, Thiene G. Sudden cardiac death with normal heart: molecular autopsy. Cardiovasc Pathol 2010;19(6):321-5.

12. Calore C, De Bortoli M, Romualdi C, Lorenzon A, Angelini A, Basso C, Thiene G, Iliceto S, Rampazzo A, Melacini P. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life. J Med Genet 2015;52(5):338-47.

13. Chen YH, Liu JM, Hsu RJ, Hu SC, Harn HJ, Chen SP, Jeng JR, Wu CL, Ho JY, Yu CP. Angiotensin converting enzyme DD genotype is associated with acute coronary syndrome severity and sudden cardiac death in Taiwan: a case-control emergency room study. BMC Cardiovasc Disord 2012; 12:6.

14. Lahtinen AM, Havulinna AS, Noseworthy PA, Jula A, Karhunen PJ, Perola M, Newton-Cheh C, Salomaa V, Kontula K. Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population. Ann Med 2013;45(4):328-35.

15. Wang K, Chen L, Liu L, Cui Y, Zhang X, Jiang J. The effects of atorvastatin on interventional therapy in patients with acute myocardial infarction. Minerva Med 2019;110(2):101-106.

16. Pokharel Y, Sharma PP, Qintar M, Lu Y, Tang Y, Jones P, Dreyer RP, Spertus JA. High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction. Atherosclerosis 2017; 266:16-23.

17. Viereck J, Thum T. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circ Res 2017;120(2):381-399.

18. Bjorkman S, Taylor HS. MicroRNAs in endometriosis: biological function and emerging biomarker candidates. J Reprod Med 2019;100(5):1135-1146.

19. Santovito D, Weber C. Zooming in on microRNAs for refining cardiovascular risk prediction in secondary prevention. Eur J Heart J 2017;38(7):524-528.

20. Poller W, Dimmel S, Heymans S, Zeller T, Haas J, Karakas M, Leistner DM, Jakob P, Nakagawa S, Blankenberg S and others. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur J Heart J 2018;39(29):2704-2716.

21. Colpaert R, Calore M. MicroRNAs in Cardiac Diseases. Cells 2019;8(7).
22. Cheng M, Yang J, Zhao X, Zhang E, Zeng Q, Yu Y, Yang L, Wu B, Yi G, Mao X and others. Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells. Nat Commun 2019;10(1):959.
23. Elia L, Condorelli G. MicroRNAs and pulmonary hypertension: a tight link. Cardiovasc Res 2016;111(3):163-4.
24. Oner T, Arslan C, Yenmis G, Arapi B, Tel C, Aydemir B, Sultuybek GK. Association of NFKB1A and microRNAs variations and the susceptibility to atherosclerosis. J Genet 2017;96(2):251-259.
25. Komal S, Yin JJ, Wang SH, Huang CZ, Tao HL, Dong JZ, Han SN, Zhang LR. MicroRNAs: Emerging biomarkers for atrial fibrillation. J Cardiol 2019;74(6):475-482.
26. Liu X, Zhang Y, Du W, Liang H, He H, Zhang L, Pan Z, Li X, Xu C, Zhou Y and others. MiR-223-3p as a Novel MicroRNA Regulator of Expression of Voltage-Gated K+ Channel Kv4.2 in Acute Myocardial Infarction. Cell Physiol Biochem 2016;39(1):102-14.
27. Peng XP, Huang L, Liu ZH. miRNA-133a attenuates lipid accumulation via TR4-CD36 pathway in macrophages. Biochimie 2016; 127:79-85.
28. Chen X, Zhang L, Su T, Li H, Huang Q, Wu D, Yang C, Han Z. Kinetics of plasma microRNA-499 expression in acute myocardial infarction. J Thorac Dis 2015;7(5):890-6.
29. Courts C, Madea B. Micro-RNA - A potential for forensic science? Forensic Sci Int 2010;203(1-3):106-11.
30. Pinchi E, Frati P, Aromatario M, Cipolloni L, Fabbri M, La Russa R, Maiese A, Neri M, Santurro A, Scopetti M and others. miR-1, miR-499 and miR-208 are sensitive markers to diagnose sudden death due to early acute myocardial infarction. J Cell Mol Med 2019;23(9):6005-6016.
31. Qin D, Wang X, Li Y, Yang L, Wang R, Peng J, Essandoh K, Mu X, Peng T, Han Q and others. MicroRNA-223-5p and -3p Cooperatively Suppress Necroptosis in Ischemic/Reperfused Hearts. J Biol Chem 2016;291(38):20247-59.
32. Ren L, Wang Q, Chen Y, Ma Y, Wang D. Involvement of MicroRNA-133a in the Protective Effect of Hydrogen Sulfide against Ischemia/Reperfusion-Induced Endoplasmic Reticulum Stress and Cardiomyocyte Apoptosis. Pharmacology 2019;103(1-2):1-9.
33. Chen Y, Ye X, Yan F. MicroRNA 3113-5p is a novel marker for early cardiac ischemia/reperfusion injury. Diagn Pathol 2019;14(1):121.
34. Song Z, Gao R, Yan B. Potential roles of microRNA-1 and microRNA-133 in cardiovascular disease. Rev Cardiovasc Med 2020;21(1):57-64.
35. Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, Cai L. miRNAs in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin 2018;39(7):1073-1084.
36. Gurha P. MicroRNAs in cardiovascular disease. Curr Opin Cardiol 2016;31(3):249-54.
37. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A and others. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105(30):10513-8.
38. Sun T, Zhang L, Li X, Chen F, Li Y, Ma X, Yu F. MicroRNA-1 and Circulating Microvesicles Mediate the Protective Effects of Dantonic in Acute Myocardial Infarction Rat Models. Front Physiol 2018; 9:664.
39. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010;31(6):659-66.
40. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H and others. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007;13(4):486-91.

41. Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, van Berkel TJ, Biessen EA. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 2010;394(3):792-7.

42. Ding H, Hu CX, Xu JK. Circulating miR-106a may Function as Potential Biomarkers in Patients with Coronary Artery Disease. Clin Lab 2019;65(10).

43. Wang YS, Zhou J, Hong K, Cheng XS, Li YG. MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase. Cell Physiol Biochem 2015;35(4):1546-56.

44. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009;69(14):5776-83.

45. Zhao J, Yu H, Yan P, Zhou X, Wang Y, Yao Y. Circulating MicroRNA-499 as a Diagnostic Biomarker for Acute Myocardial Infarction: A Meta-analysis. Dis Markers 2019; 2019:6121696.

46. Shi Y, Han Y, Niu L, Li J, Chen Y. MiR-499 inhibited hypoxia/reoxygenation induced cardiomyocytes injury by targeting SOX6. Biotechnol Lett 2019;41(6-7):837-847.

47. He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M, Xie B, Gao XG, Wang YW. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci 2011; 18:22.

48. Yao L, Zhou B, You L, Hu H, Xie R. LncRNA MIAT/miR-133a-3p axis regulates atrial fibrillation and atrial fibrillation-induced myocardial fibrosis. Mol Biol Rep 2020;47(4):2605-2617.

49. Yuan L, Liu X, Chen F, Zhang L, Chen X, Huang Q, Wu D, Yang C, Han Z. Diagnostic and Prognostic Value of Circulating MicroRNA-133a in Patients with Acute Myocardial Infarction. Clin Lab 2016;62(7):1233-1241.

50. Zhao J, Yu H, Yan P, Zhou X, Wang Y, Yao Y. Circulating MicroRNA-499 as a Diagnostic Biomarker for Acute Myocardial Infarction: A Meta-analysis. Dis Markers 2019; 2019:6121696.

51. Li L, Li S, Wu M, Chi C, Hu D, Cui Y, Song J, Lee C, Chen H. Early diagnostic value of circulating microRNAs in patients with suspected acute myocardial infarction. J Cell Physiol 2019;234(8):13649-13658.

52. Kakimoto Y, Kamiguchi H, Ochiai E, Satoh F, Osawa M. MicroRNA Stability in Postmortem FFPE Tissues: Quantitative Analysis Using Autoptic Samples from Acute Myocardial Infarction Patients. PLoS One 2015;10(6): e0129338.

53. Kokkat TJ, Patel MS, McGarvey D, LiVolsi VA, Baloch ZW. Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. Biopreserv Biobank 2013;11(2):101-6.

54. Greytak SR, Engel KB, Bass BP, Moore HM. Accuracy of Molecular Data Generated with FFPE Biospecimens: Lessons from the Literature. Cancer Res 2015;75(8):1541-7.

55. Zamarian V, Catozzi C, Ressel L, Finotello R, Ceciliani F, Vilafranca M, Altimira J, Lecchi C. MicroRNA Expression in Formalin-Fixed, Paraffin-Embedded Samples of Canine Cutaneous and Oral Melanoma by RT-qPCR. Vet Pathol 2019;56(6):848-855.

Tables

Table 1. Basic information of the collected human cases.
| Cause of death     | Group                  | n  | Male/female | Age (years) | Postmortem Interval (h) | heart weight (g) |
|--------------------|------------------------|----|-------------|-------------|-------------------------|-----------------|
| CO intoxication    | Negative control       | 14 | 7/7         | 30.29±3.11  | 7.29±1.92               | 298.9±32.71     |
| Fatal injury       | Positive control       | 14 | 9/5         | 45.00±4.01**| 8.07±1.96               | 312.5±20.18     |
| ASCVD              | Sudden cardiac death   | 16 | 14/2        | 62.69±3.06***## | 3.75±0.66#            | 455.6±10.49***### |
| AMI                | Sudden cardiac death   | 18 | 14/4        | 42.11±3.08*&&& | 5.50±1.27            | 377.8±27.32&    |

CO, carbon monoxide. ASCVD, atherosclerotic cardiovascular diseases (with evidence of heart dysfunction). AMI, acute myocardial infarction (without notable heart changes at autopsy). *p<0.05, **p<0.01, and ***p<0.001 vs. CO intoxication. #p<0.05, ##p<0.01, and ###p<0.001 vs. Fatal injury. &p<0.05 and &&&p<0.001 vs. ASCVD.

**Table 2. Primer sequences used in this study**

| miRNAs            | Primer Sequences 5’-3’                   |
|-------------------|------------------------------------------|
| hsa-miR-3113-5p   | GTCCTGGCCCTGGTCCGGGTCC                   |
| hsa-miR-499a-5p   | TTAAGACCTTGCACTGATGTTC                   |
| hsa-miR-223-3p    | TGGCAGTTTGCTGAATACCCCA                   |
| hsa-miR-133a-3p   | TTTGGTCCCCTAACCAGCTG                     |

**Table 3. Receive operating characteristic (ROC) analysis of miRNAs.**
|                   | AUC     | Std.Error | P value   | LB(95%)  | UB(95%)  | Sensitivity | Specificity | Youden index |
|-------------------|---------|-----------|-----------|----------|----------|-------------|-------------|--------------|
| miR-3113-5p SCD vs Fatal injury | 0.7839  | 0.06823   | 0.004091  | 0.6501   | 0.9176   | 68.75%      | 83.33%      | 0.52         |
| miR-3113-5p SCD vs CO intoxication | 0.8281  | 0.06175   | 0.0009054 | 0.7071   | 0.9492   | 68.75%      | 91.67%      | 0.60         |
| miR-223-3p SCD vs Fatal injury | 0.9043  | 0.05161   | 0.0002037 | 0.8031   | 1.006    | 83.33%      | 88.89%      | 0.72         |
| miR-223-3p SCD vs CO intoxication | 0.8917  | 0.04755   | 0.0001753 | 0.7984   | 0.9849   | 75%         | 100%        | 0.75         |
| miR-499a-5p SCD vs Fatal injury | 0.8971  | 0.05094   | 0.0001582 | 0.7972   | 0.9969   | 82.35%      | 90%         | 0.72         |
| miR-499a-5p SCD vs CO intoxication | 0.8853  | 0.05518   | 0.0002463 | 0.7771   | 0.9935   | 97.06%      | 70%         | 0.67         |
| miR-133a-3p SCD vs Fatal injury | 0.7851  | 0.07063   | 0.002743  | 0.6466   | 0.9235   | 67.65%      | 76.92%      | 0.45         |
| miR-133a-3p SCD vs CO intoxication | 0.8743  | 0.05356   | 0.0002201 | 0.7693   | 0.9793   | 64.71%      | 100%        | 0.65         |

AUC, area under the curve; LB, lower bound; UB, upper bound.

**Table 4. Receive operating characteristic (ROC) analysis of miRNAs.**
| AUC   | Std.Error | P value  | LB(95%) | UB(95%) | Sensitivity | Specificity | Youden index |
|-------|-----------|----------|---------|---------|-------------|-------------|--------------|
| miR-3113-5p & miR-223-3p | 0.8667    | 0.06520  | 0.0004180 | 0.7388  | 0.9945      | 82.35%      | 80%          | 0.62        |
| miR-3113-5p & miR-499a-5p | 0.8510    | 0.07165  | 0.0007310 | 0.7105  | 0.9915      | 100%        | 66.67%       | 0.67        |
| miR-3113-5p & miR-133a-3p | 0.7686    | 0.08438  | 0.009717  | 0.6032  | 0.9341      | 70.59%      | 80%          | 0.51        |
| miR-499a-5p & miR-133a-3p | 0.7569    | 0.08320  | 0.01070  | 0.5938  | 0.9201      | 66.67%      | 81.25%       | 0.48        |
| miR-223-3p & miR-499a-5p | 0.7741    | 0.08562  | 0.007487  | 0.6062  | 0.9419      | 88.89%      | 60%          | 0.49        |
| miR-223-3p & miR-133a-3p | 0.7407    | 0.08709  | 0.01881  | 0.5700  | 0.9115      | 66.67%      | 80%          | 0.47        |

AUC, area under the curve; LB, lower bound; UB, upper bound.

**Figures**

**Figure 1**

Representative photographs of the morphological changes in the heart tissues of fatal injury, carbon monoxide (CO) intoxication, atherosclerotic cardiovascular disease (ASCVD) and acute myocardial infarction by H&E staining and PicroSirius Red (PSR) staining. Scale bar=200μm.